Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5440_Библиотеки_им_академика_М_И_Перельмана.pdf
eferences 283
88 Rizvi, S.A.A., Einstein, G.P., Tulp, O.L. et al. (2022). Introduction to traditional medicine and
their role in prevention and treatment of emerging and re-emerging diseases. Biomolecules
12 (10): 1442.
89 Parmar, G., Pundarikakshudu, K., and Balaraman, R. (2019). Anti-anaphylactic and antiasthmatic
activity of Euphorbia thymifolia L. on experimental animals. Journal of Traditional and
Complementary Medicine 9 (1): 60–65.
90 Parmar, G., Pundarikakshudu, K., Balaraman, R., and Sailor, G. (2018). Amelioration of
anaphylaxis, mast cell degranulation and bronchospasm by Euphorbia hirta L. extracts in
experimental animals. Beni-Suef University Journal of Basic and Applied Sciences 7 (1): 127–134.
91 Kumar, S., Verma, M., Hajam, Y.A., and Kumar, R. (2024). Honey infused with herbs: a boon to
cure pathological diseases. Heliyon 10 (1): e23302.
92 Maheshwari, R.A., Parmar, G.R., Hinsu, D. et al. (2020). Novel therapeutic intervention of
coenzyme Q10 and its combination with pioglitazone on the mRNA expression level of
adipocytokines in diabetic rats. Life Sciences 258: 118155.
93 Parmar, G. and Pundarikakshudu, K. (2020). Determination and validation assay for total
phenolic content in two Euphorbiaceous plants by Folin Ciocalteu method. International Journal
of Pharmaceutical Research 12 (Suppl 1): 608–612.
94 Hashem, S., Ali, T.A., Akhtar, S. et al. (2022). Targeting cancer signaling pathways by natural
products: exploring promising anti-cancer agents. Biomedicine & Pharmacotherapy 150: 113054.
95 Shah, A., Patel, V., Jain, M., and Parmar, G. (2023). Network pharmacology and systems biology
in drug discovery. In: CADD and Informatics in Drug Discovery, 231–252. Singapore: Springer
Nature Singapore.
96 Gonzalez, H., Hagerling, C., and Werb, Z. (2018). Roles of the immune system in cancer: from
tumor initiation to metastatic progression. Genes & Development 32 (19–20): 1267–1284.
97 Shah, A., Parmar, G., and Seth, A.K. (2021). In silico discovery of novel flavonoids as poly ADP
ribose polymerase (PARP) inhibitors. Current Computer-Aided Drug Design 17 (3): 344–350.
98 Zhong, L., Li, Y., Xiong, L. et al. (2021). Small molecules in targeted cancer therapy: advances,
challenges, and future perspectives. Signal Transduction and Targeted Therapy 6 (1): 201.
99 Iqbal, N. and Iqbal, N. (2014). Human epidermal growth factor receptor 2 (HER2) in cancers:
overexpression and therapeutic implications. Molecular Biology International 2014: 852748.
100 Yin, L., Duan, J.-J., Bian, X.-W., and Yu, S.-c. (2020). Triple-negative breast cancer molecular
subtyping and treatment progress. Breast Cancer Research 22 (1): 61.
101 Harbeck, N., Penault-Llorca, F., Cortes, J. et al. (2019). Breast cancer. Nature Reviews Disease
Primers 5 (1): 66.
102 Nitta, H., Kelly, B.D., Allred, C. et al. (2016). The assessment of HER2 status in breast cancer: the
past, the present, and the future. Pathology International 66 (6): 313–324.
103 Kapoor, D., Vijayvergiya, R., and Dhawan, V. (2014). Terminalia arjuna in coronary artery disease:
ethnopharmacology, pre-clinical, clinical & safety evaluation. Journal of Ethnopharmacology
155 (2): 1029–1045.
104 Bachheti, R.K., Worku, L.A., Gonfa, Y.H. et al. (2022). Prevention and treatment of cardiovascular
diseases with plant phytochemicals: a review. Evidence-based Complementary and Alternative
Medicine: Ecam 2022: 5741198.
105 Tao, W., Xu, X., Wang, X. et al. (2013). Network pharmacology-based prediction of the active
ingredients and potential targets of Chinese herbal Radix Curcumae formula for application to
cardiovascular disease. Journal of Ethnopharmacology 145 (1): 1–10.
106 Lu, M., Yin, J., Zhu, Q. et al. (2023). Artificial intelligence in pharmaceutical sciences. Engineering
27: 37–69.
12 Network-based Methods in Drug Discovery284
107 Li, W., Yuan, G., Pan, Y. et al. (2017). Network pharmacology studies on the bioactive compounds
and action mechanisms of natural products for the treatment of diabetes mellitus: a review.
Frontiers in Pharmacology 8: 74.
108 Rogal, J., Zbinden, A., Schenke-Layland, K., and Loskill, P. (2019). Stem-cell based organ-on-a
chip models for diabetes research. Advanced Drug Delivery Reviews 140: 101–128.
109 Li, H., Yang, Y., Hong, W. et al. (2020). Applications of genome editing technology in the targeted
therapy of human diseases: mechanisms, advances and prospects. Signal Transduction and
Targeted Therapy 5 (1): 1.
110 Halayal, R.Y., Bagewadi, Z.K., Maliger, R.B. et al. (2023). Network pharmacology based anti
diabetic attributes of bioactive compounds from Ocimum gratissimum L. through computational
approach. Saudi Journal of Biological Sciences 30 (9): 103766.
111 Parmar, G., Pundarikakshudu, K., and Balaraman, R. (2017). Antidiabetic and antihyperlipidemic
activity of Euphorbia thymifolia L. extracts on streptozotocin-nicotinamide induced type 2
diabetic rats. Journal of Applied Pharmaceutical Science 7 (8): 078–084.
112 Caesar, L.K. and Cech, N.B. (2019). Synergy and antagonism in natural product extracts: when
1 + 1 does not equal 2. Natural Product Reports 36 (6): 869–888.
113 Thomford, N.E., Senthebane, D.A., Rowe, A. et al. (2018). Natural products for drug discovery in
the 21st century: innovations for novel drug discovery. International Journal of Molecular Sciences
19 (6): 1578.
114 Wainwright, C.L., Teixeira, M.M., Adelson, D.L. et al. (2022). Future directions for the discovery
of natural product-derived immunomodulating drugs: an IUPHAR positional review.
Pharmacological Research 177: 106076.
115 Li, L., Yang, L., Yang, L. et al. (2023). Network pharmacology: a bright guiding light on the way to
explore the personalized precise medication of traditional Chinese medicine. Chinese Medicine
18 (1): 146.
116 You, Y., Lai, X., Pan, Y. et al. (2022). Artificial intelligence in cancer target identification and drug
discovery. Signal Transduction and Targeted Therapy 7 (1): 156.
117 Parmar, G., Chudasama, J.M., Shah, A., and Patel, A. (2023). In silico pharmacology and drug
repurposing approaches. In: CADD and Informatics in Drug Discovery, 253–281. Singapore:
Springer Nature Singapore.
285
13.1 Introduction
In the relentless pursuit of novel therapeutic solutions, pharmaceutical research continually
explores the vast array of natural compounds. These compounds, found abundantly in nature,
offer a treasure trove of chemical diversity and biological activity, making them promising candi-
dates for drug development [1]. However, harnessing the full potential of natural products for
medicinal purposes presents numerous challenges, including intricate chemical structures, lim-
ited bioavailability, and potential side effects. To overcome these hurdles and expedite the discov-
ery of effective drugs derived from natural sources, scientists have turned to rational drug
design – an approach rooted in molecular biology, biochemistry, and computational chemistry [2].
This chapter delves into the intricacies of rational drug design, exploring its methodologies, appli-
cations, and implications for advancing drug discovery.
Structure-guided computer-aided drug design is a cornerstone of rational drug design, particu-
larly for targets with known three-dimensional structures. By elucidating the binding interactions
between target proteins and potential drug candidates, this approach enables researchers to design
small molecules with enhanced specificity and efficacy [3]. Utilizing techniques such as X-ray
crystallography and nuclear magnetic resonance (NMR) spectroscopy, scientists can visualize the
three-dimensional structure of target proteins and identify key binding sites [4]. Virtual screening
(VS) of large chemical libraries further expedites the identification of promising drug candidates,
laying the foundation for subsequent experimental validation and optimization.
In the era of precision medicine, state-of-the-art methodologies play a pivotal role in driving
drug discovery forward. Resources such as the Protein Data Bank (PDB), the National Cancer
Institute (NCI) database, and computational tools provide researchers with invaluable resources
for VS and structural analysis. High-throughput screening (HTS) platforms and molecular mode-
ling software further streamline the drug discovery process, enabling rapid iteration and optimiza-
tion of lead compounds [5].
While modern drug discovery relies heavily on cutting-edge technologies, traditional medicinal
practices offer valuable insights into the therapeutic potential of natural compounds. Ancient
13
Rational Design of Natural Products for Drug Discovery
Ankita Kashyap
1
, Anupam Sarma
2
, Bhrigu Kumar Das
3
, and Ashis Kumar Goswami
4
1
Institute of Pharmacy, Assam Medical College and Hospital, Dibrugarh, India
2
Advanced Drug Delivery Laboratory, School of Pharmaceutical Sciences, Girijananda Chowdhury University, Guwahati, India
3
Pharmacology and Toxicology Laboratory, School of Pharmaceutical Sciences, Girijananda Chowdhury University, Guwahati, India
4
Department of Pharmaceutical Sciences, Faculty of Science and Engineering, Dibrugarh University, Assam, India
286
Asian herbal medicine, such as Ayurveda, emphasizes the synergistic effects of herbal combina-
tions, paving the way for novel approaches to drug discovery. By integrating traditional wisdom
with modern scientific techniques, researchers can unlock new therapeutic avenues and address
unmet medical needs more effectively [6].
Global gene expression profiling provides unprecedented insights into disease pathogenesis and
therapeutic responses. Platforms such as Serial Analysis of Gene Expression (SAGE) and microar-
ray analysis enable researchers to characterize the transcriptional profiles of diseased tissues and
identify dysregulated genes associated with disease progression. Bioinformatics tools facilitate the
analysis and interpretation of vast genomic datasets, guiding the selection, and optimization of
drug candidates with the highest therapeutic potential [7].
In conclusion, rational drug design represents a paradigm shift in drug discovery, integrating
cutting-edge technologies with traditional wisdom to unlock nature’s pharmacological arsenal. By
harnessing the power of computational modeling, structural biology, and genomic analysis,
researchers can expedite the discovery and development of safe and effective therapeutics. As we
continue to unravel the complexities of disease biology and molecular interactions, rational drug
design will remain at the forefront of drug discovery, shaping the future of medicine and improv-
ing patient outcomes.
13.2 Natural Products for the Development of New Drugs
Natural products constitute a diverse array of chemical compounds biosynthesized by living organ-
isms, encompassing plants, animals, and microorganisms. Endowed with a rich history of applica-
tion as curative agents dating back millennia, these compounds hold profound significance due to
their inherent bioactivity and promising therapeutic attributes. Alkaloids, flavonoids, terpenes,
and steroids are among the myriad subclasses of natural products, each contributing distinct
molecular structures and pharmacological potential. Their pivotal role in contemporary drug dis-
covery underscores their value as sources of novel therapeutic agents. Natural products, with their
complex and intricate chemical profiles, continue to captivate scientific interest as they unveil a
treasure trove of potential therapeutic preparations, perpetuating their legacy as indispensable
contributors to the advancement of medicine [8]. Figure 13.1 shows the components or fundamen-
tal steps involved in developing new drugs from natural products.
Natural products for the development of new drugs
Identification of
potential sources
Post-marketing
surveillance
Lead optimization
Bioactivity
screening
Isolation and
characterization
Mechanism of
action studies
Preclinical studies
Clinical
development
ADME/toxicity
assessment
Patenting and
intellectual property
Figure 13.1 Components of the process of development of new drugs from natural products.
287
They are essential to the drug development process because of their unique chemical originality
and deep biological activity. These substances have played a significant role in the pharmaceutical
industry throughout history, accounting for around 30% of all drug sales worldwide. Natural prod-
ucts are unmatched resources because they have a vast reservoir of chemical variety, attractive
drug-like characteristics, and the ability to interact with various biological target proteins. Their
historical role as foundational lead compounds in drug discovery is augmented by an escalating
recognition of their intricate structural and stereochemical attributes. In contemporary drug devel-
opment initiatives, the enduring relevance of natural products persists, positioning them as invalu-
able reservoirs for the innovation and creation of novel therapeutic drugs [9, 10].
Sales of recombinant peptides and protein molecules are on the rise, but low-molecular-mass
chemicals continue to be the gold standard for treating human diseases. This is mainly because of
their greater compliance and bioavailability. Natural products have historically been the source of
many novel therapeutic methods, demonstrating their creative potential in medication discovery
and development. Natural products have had a significant impact on drug development, but pres-
ently, they are not given as much attention because of the significant work involved in active prin-
ciple isolation and structure elucidation. To effectively compete with combinatorial chemistry,
new approaches in natural product chemistry are needed to meet the requirement for large test
samples in the process of HTS. Pharmaceutical companies currently spend about $350 million US
on the development of new drugs. It is predicted that the course of medication development and
discovery in the future will depend on advances in molecular science, the biology of cells, and
genome engineering to improve therapeutic target clarification and lead discovery. The human
genome is almost complete, which means that a much larger pool of possible pharmacological
targets will become available for consideration during the drug discovery phase. The ability of HTS
to test an increasing number of samples highlights the significance of creating large chemical col-
lections with improved structural diversity for more successful drug development programs [11].
The landscape of natural product drug discovery confronts formidable challenges arising from
the extensive chemical diversity inherent in these compounds, coupled with technical barriers. A
comprehensive survey involving 52 experts underscored a perceptible dissonance between the
acknowledged potential of natural products and the efficacy of prevailing drug discovery strategies.
Paramount among the challenges are the constrained supply of compounds, hurdles in target
identification, and the complexities associated with scale-up for commercialization. In response to
these impediments, a strategic amalgamation of rational approaches, cutting-edge technologies,
and computational methodologies is being orchestrated [12]. This integration encompasses
structure- and ligand-based design techniques, ADMET (absorption, distribution, metabolism,
excretion, and toxicity) profiling, and the utilization of cheminformatics for the systematic
organization and interpretation of data. Despite the intricacies posed by these challenges, the
intrinsic value of natural products in drug discovery endures as ongoing efforts strive to harness
their potential through innovative methodologies and technologies [13].
Contemporary research in medicinal plant-based drug discovery adopts a multifaceted approach,
integrating fractionation guided by bioassay, combinatorial chemistry, botany, phytochemistry,
and biochemistry methodologies. In the quest for safe and effective drugs, natural sources con-
tinue to be explored as valuable reservoirs of pharmacological leads against severe diseases like
diabetes, cardiovascular disorders, and cancer. The escalating global demand for reliable therapeu-
tics has prompted a resurgence in exploring natural resources for potential treatments of chronic
and life-threatening illnesses. However, the sector faces significant obstacles, particularly in the
marketing and scaling up of active compounds, meaning that only a small percentage of lead mol-
ecules may advance to the stage of medication development. For the effective investigation and
288
development of medicinal compounds derived from natural resources, it is essential to take a
methodical and scientific approach to overcome these challenges [14].
The foundational role of conventional techniques persists as paramount in the identification of
potential therapeutic agents. Historically, natural products have stood as invaluable reservoirs of drug
leads, with bio-guided fractionation being a conventional approach wherein crude extracts undergo
sequential separation and testing until one single active ingredient is found. However, this approach
is characterized by a laborious and slow procedure. In response to these limitations, contemporary
strategies, such as metabolomics and chemometrics, have emerged to enhance lead-finding efficiency
by establishing correlations between chemical and biological data. Despite the inherent challenges,
natural products maintain their pivotal status as a crucial source for the discovery of novel drugs,
evolving alongside innovative methodologies aimed at optimizing the drug discovery process [15].
13.3 Criteria for Selecting Natural Products for Drug Design
The selection of natural products for drug design involves carefully considering several criteria to
identify promising candidates with therapeutic potential. By carefully evaluating natural products
based on these criteria, researchers can identify promising drug design and development candidates,
ultimately discovering novel therapeutics with improved efficacy and safety profiles. These include:
1) Bioactivity: Natural products should exhibit specific biological activities relevant to the targeted
disease or condition, such as antimicrobial, anti-inflammatory, or anticancer properties. Screening
assays and bioassays are commonly used to assess the bioactivity of natural products [16].
2) Pharmacological properties: Natural products should possess favorable pharmacokinetic
and pharmacodynamic properties, including ADMET. Compounds with suitable ADMET pro-
files are more likely to be developed into successful drugs [17, 18].
3) Chemical diversity: Natural products offer various chemical structures, representing diverse
scaffolds and functional groups. Selecting compounds with structural diversity increases the like-
lihood of identifying novel drug leads and optimizing their pharmacological properties [19, 20].
4) Synthetic accessibility: The feasibility of synthesizing or obtaining natural products in suffi-
cient quantities for further research and development is essential. Compounds that are readily
accessible or amenable to chemical synthesis are preferred for drug design efforts [21, 22].
5) Availability and sustainability: Natural products should be obtainable from sustainable and
environmentally friendly sources to ensure long-term availability. Ethical considerations
regarding biodiversity conservation and traditional knowledge protection should also be
considered [23].
6) Target specificity: Natural products should demonstrate selectivity toward the intended
molecular targets associated with the diseases of interest. Understanding the mechanism of
action and target engagement is crucial for assessing the therapeutic potential of natural
products [24].
13.4 Importance of Biodiversity in Sourcing Natural Products
The diversity and variability of life on Earth is known as biodiversity, and it is commonly measured by
differences found in species, genetic makeup, and ecosystems [25]. Natural products (NPs) are the
end-products of gene expression, also known as “secondary metabolites.” They are a reliable and vital
289
source of effective medication leads from Earth’s biodiverse flora and fauna [26]. Since ancient times,
the development of pharmaceutical products has been aided by using natural products for medicinal
purposes. Drug research and discovery depend on biodiversity conservation since its loss eliminates
previously unknown genetic and natural chemical resources. The most well-known pharmacological
drugs from natural sources are caffeine, acetylsalicylic acid (Aspirin), and plants’ antimalarial agents
Quinine and Artemisinin [25]. Similarly, the majority of known antibiotics (such as Streptomycin and
Penicillin) and antifungal drugs (such as Griseofulvin) have been discovered through soil fungi [27].
Biodiversity, encompassing the vast array of life forms and ecosystems on Earth, is the corner-
stone of natural product sourcing for drug discovery. It represents the collective genetic, species,
and ecological diversity in different environments, ranging from tropical rainforests to marine eco-
systems. Within this biological diversity lie invaluable reservoirs of secondary metabolites, known
as natural products, which organisms have evolutionarily honed for various ecological purposes.
These natural products exhibit a remarkable array of chemical structures and bioactivities, making
them promising candidates for drug development [28]. The importance of biodiversity in sourcing
natural products for drug discovery cannot be overstated. It provides researchers with an extensive
library of chemical compounds with diverse pharmacological properties, offering potential solu-
tions to various human health conditions. The loss of biodiversity poses a significant threat to drug
discovery efforts, as it not only diminishes the availability of natural compounds but also erases the
genetic and chemical diversity that could hold the key to novel therapeutics. As such, conservation
efforts to preserve biodiversity are crucial to safeguarding these invaluable resources for future
drug development endeavors [29].
Historically, natural products have played a pivotal role in developing pharmacological agents,
serving as the foundation for many essential medications. Examples abound, from discovering
antibiotics like penicillin to developing anticancer drugs such as vincristine and vinblastine derived
from the Madagascar periwinkle. Moreover, recent advancements in drug discovery have contin-
ued to leverage biodiversity, with discoveries ranging from novel antidiabetic agents sourced from
plants to marine-derived compounds with potential antiparasitic and anticancer properties [30].
Piptoporus betulinus, another type of fungus that grows on birches, was cooked to create charcoal,
which has antibacterial and disinfecting properties, and different therapeutic cures have even been
supplied by marine organisms. A drink made from the red algae Chondrus crispus and Mastocarpus
stellatus was used to treat colds, sore throats, and chest illnesses, including tuberculosis. It was also
reported that boiling the algae in milk or water made them effective against burns and kidney
problems [31]. Also, compounds like Zamamidine D isolated from Amphimedon sp., Protulactone
A isolated from Aspergillus sp., Gombasterols from Clathria gombawuiensis, Lamellodysidines
from Lamellodysidea herbacea, Sulawesins from Psammocinia sp. have different medicinal proper-
ties [32]. In essence, preserving biodiversity is paramount for sustaining the reservoirs of natural
products that hold immense promise for future drug discovery efforts. By conserving Earth’s bio-
logical diversity, we can ensure continued access to the vast array of chemical compounds that
nature offers, thereby advancing the frontiers of pharmaceutical research and improving global
health outcomes [30].
13.5 Structural Elucidation of Natural Products
Over the past century, significant advancements have been made in elucidating the structures of
natural products, leading to a profound understanding of their chemical composition and biologi-
cal activity. This progress has been driven by innovative analytical techniques, methodologies, and
290
advancements in computational chemistry and spectroscopic instrumentation [18]. Historically,
the elucidation of natural product structures relied heavily on classical methods such as chemical
degradation, elemental analysis, and optical rotation measurements. However, the advent of NMR
spectroscopy in the mid-20th century revolutionized the field by providing detailed information
about the connectivity of atoms within molecules. NMR spectroscopy enabled researchers to elu-
cidate complex structures precisely and determine stereochemistry [33]. In parallel, mass spec-
trometry (MS) emerged as a powerful tool for analyzing natural products, offering insights into
molecular weight, fragmentation patterns, and elemental composition. The development of high-
resolution MS instruments further enhanced the accuracy and sensitivity of structural elucidation
studies, enabling the characterization of compounds present in minute quantities [34]. The syn-
ergy between NMR spectroscopy and MS has facilitated the elucidation of challenging natural
product structures, including complex alkaloids, terpenoids, and polyketides. Moreover, X-ray
crystallography has played a pivotal role in confirming the three-dimensional arrangement of
atoms in crystalline compounds, providing invaluable insights into molecular architecture and
stereochemistry [35]. In recent years, advancements in computational chemistry and bioinformat-
ics have complemented experimental approaches, enabling the prediction and modeling of natural
product structures based on spectroscopic data and molecular modeling techniques. These compu-
tational tools have expedited the structural elucidation process and facilitated the discovery of
novel bioactive compounds with therapeutic potential. Overall, the past century has witnessed
remarkable progress in elucidating natural product structures, driven by interdisciplinary collabo-
rations and technological innovations. Continued advancements in analytical techniques and
computational methods are expected to further research in natural product chemistry, unlocking
new avenues for drug discovery and development [36].
13.6 In Silico Computational Tools for Rational Drug Discovery
from Natural Sources
13.6.1 Molecular Docking and Virtual Screening Techniques for Predicting
Ligand–Receptor Interactions
Molecular docking stands as a computational cornerstone in drug discovery, employed to forecast
the interaction dynamics between a small molecule (ligand) and a target protein (receptor). Within
the realm of natural product drug discovery, this method assumes a pivotal role in scrutinizing
potential bioactive compounds derived from diverse sources, including plants, fungi, and marine
species. The primary objective is the discernment of natural products capable of interacting with
specific target proteins implicated in various diseases, ranging from cancer to neurodegenerative
disorders. By facilitating the screening and identification of promising lead compounds, molecular
docking becomes an instrumental tool, propelling the subsequent development of these com-
pounds into therapeutic agents. This computational approach thus serves as a strategic bridge
connecting the realms of computational science and pharmaceutical innovation in the pursuit of
novel and effective treatments [37].
Molecular docking emerges as an invaluable asset, facilitating the discernment of potential bio-
active molecules sourced from nature and thus catalyzing the quest for innovative therapeutic
agents. This method has demonstrated efficacy in pinpointing macromolecular targets for natural
products, thereby contributing to the development of drugs with heightened safety and efficacy
profiles [38]. Molecular docking’s utility extends to the expedited identification of bioactive
291
13.6 In Silico
phytochemicals, streamlining the preliminary validation process. Its versatility is evident in
medication design based on structure, exemplified by its application in the search for potential
inhibitors against COVID-19 [39, 40]. In essence, molecular docking assumes a pivotal role in
unlocking the therapeutic potential inherent in natural products, navigating the complex land-
scape of drug discovery with precision and efficiency [41].
Many natural compounds have large, pliable macrocyclic structures that interact with their tar-
gets using several sites of contact. Natural products are attractive scaffolds because of their unique
combination of limited elasticity and large surface area, especially for difficult therapeutic targets
and protein–protein interaction inhibition. Their preference for binding at target surfaces as
opposed to deep pockets highlights why medicinal chemistry campaigns find them appealing.
Their role as final therapeutic agents is no longer limited by the increasing ability to change these
chemicals through semisynthetic modifications or biosynthetic processes, which turns them into
suitable starting points for medicinal chemistry attempts. The logical improvement of molecular
docking in modern medicinal chemistry, guided by knowledge of the complex binding mecha-
nisms and adaptable scaffolds present in macrocyclic natural products and their analogs, greatly
increases the effectiveness of drug development initiatives. This sophisticated method emphasizes
how crucial molecular docking is to maximize the potential of natural macrocyclic compounds for
contemporary medicinal science [42].
An essential bioinformatics method for examining and understanding ligand–receptor interac-
tions is molecular docking, which provides information on the molecular targets of various ligands.
Through its revolutionary role in chemical separation and medication development from herbal
sources, this method leverages the long history of using herbs as treatments for a wide range of
illnesses. Phytochemicals and drug makers are increasingly concentrating on developing innova-
tive compounds derived mostly from herbs, hence lowering required quantities in the pursuit of
safer and more effective medications. As an example of this paradigm, a plant that is commonly
found in India and is well-known for its use in the treatment of urinary disorders, Rotula aquatica
Lour was thoroughly investigated. After its root was extracted, active chemicals were produced,
and molecular docking analysis was carried out between the 3-O-acetyl-11-keto-β-boswellic acid,
an isolated bioactive molecule, and Tamm–Horsfall protein (THP). This investigation demon-
strates the tactical application of molecular docking techniques in clarifying the medical applica-
tion of natural chemicals derived from herbs, as it found possible interactions that may imply the
prevention of calcium oxalate crystallization [43].
A computational method used in drug development called VS is particularly useful for finding
putative bioactive chemicals. Structure-based VS utilizes two primary methodologies: (i) molecu-
lar docking, which involves docking databases of thousands of compounds onto the active site of
a target of interest to pinpoint top-ranked compounds and (ii) inverse docking, wherein a com-
pound of interest is docked against a variety of targets to unveil potential new targets, as implied
by its name. Figure13.2 shows the molecular docking mechanism and inverse docking mechanism.
The biological significance and structural diversity of natural products highlight the importance
of VS in the field of natural product medication discovery. Though promising, the use of VS in this
area is constrained by the availability of extensive 3D databases of natural products and issues with
interoperability with HTS procedures. To mitigate these obstacles, VS must be strategically inte-
grated with traditional pharmacognosy methodologies. This provides a means of increasing the
effectiveness of natural product-based medication discovery. The integration of VS in the field of
natural product medication discovery is still being researched and developed, and this could
improve the accuracy and effectiveness of recognizing bioactive substances obtained from various
natural sources [44].
292
VS emerges as a pivotal computational technique employed to discern potential bioactive
compounds. This technique speeds up the identification of lead compounds for later drug develop-
ment by methodically analyzing large chemical databases to predict the interactions between
compounds and certain biological targets. Molecular docking, ligand-based screening, and phar-
macophore modeling represent prevalent techniques in VS, proving successful in recognizing mac-
romolecular targets for natural products. The interest in natural product-oriented drug development
initiatives has increased as a result of this success [45]. Moreover, cheminformatics techniques and
molecular modeling techniques work together to develop drugs based on natural products at a
faster rate. These tools not only organize data and interpret results but also facilitate the judicious
filtering of expansive chemical databases before experimental screening, contributing to the effi-
ciency and success of the drug discovery processes [45, 46].
VS techniques, notably molecular docking and shape-matching methodologies serve as predic-
tive tools for illuminating ligand–receptor interactions. These computational methods play a piv-
otal role in expeditiously identifying potential bioactive molecules within vast compound libraries,
significantly curtailing both time and financial expenditures. Particularly, cheminformatics
advancements have made it easier to compare databases of natural products with modern small-
molecule libraries, which has led to the successful identification of macromolecular targets for
natural products. The integration of in silico approaches has sparked a resurgence of interest in
drug discovery, offering a nuanced and efficient pathway that contributes substantive insights to
the ongoing evolution of the field [47].
Databases of compounds
Target of interest
Top ranked compound
Molecular docking Inverse docking
Top ranked target
Database of protein
Compound of interest
Figure 13.2 Two approaches used by virtual screening and molecular docking.